

The first Rituxan® (rituximab) biosimilar available in Canada^{1,2*}

Pr Truxima®
Rituximab for Injection
10 mg/mL Intravenous Infusion

**Biosimilar by design.
Biologic by essence.**

Non-Hodgkin's lymphoma (NHL)^{2†‡}

PrTRUXIMA® (rituximab for injection) is indicated for the treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy.



Rheumatoid arthritis (RA)^{2‡}

TRUXIMA® in combination with methotrexate is indicated to reduce signs and symptoms in adult patients with moderately to severely active RA who have had an inadequate response or intolerance to one or more TNF inhibitor therapies.



ANCA-associated vasculitis^{2,3‡}

TRUXIMA® in combination with glucocorticoids is indicated for the induction of remission in adult patients with severely active granulomatosis with polyangiitis (GPA, also known as Wegener's granulomatosis) and microscopic polyangiitis (MPA).



**TRUXIMA®: A proud offering
from Teva Canada Innovation.**

**Available in the EU
since 2017.^{4*}**



* Comparative clinical significance is unknown.

† Please refer to the TRUXIMA® Product Monograph to see the complete list of NHL indications.

‡ Indications have been granted on the basis of similarity between TRUXIMA® and the reference biologic drug Rituxan®.

TNF: tumour necrosis factor; ANCA: antineutrophil cytoplasmic antibody; EU: European Union.

DIN	02478382, 02478390
UPC	068510998873, 068510998880
Inventory item number	TRUXIMA® 100 mg/10 mL intravenous (IV) infusion: 85006-0002 TRUXIMA® 500 mg/50 mL IV infusion: 85007-0001
Drug category	Antineoplastic ²
Dosage form	TRUXIMA® is a sterile, clear, colourless, preservative-free liquid concentrate for IV administration ²
Drug concentration	10 mg/mL [either 100 mg (10 mL) or 500 mg (50 mL) single-use vials] ²
Route of administration	IV infusion ²
Non-medicinal ingredients	Sodium chloride, tri-sodium citrate dihydrate, polysorbate 80 and water for injection ²
Packaging	100 mg and 500 mg single-use vials 100 mg: each carton contains two 100 mg/10 mL vials (10 mg/mL) 500 mg: each carton contains one 500 mg/50 mL vial (10 mg/mL) ²
Storage instructions	TRUXIMA® vials are stable at 2–8°C. Do not use beyond expiration date stamped on carton. Keep the vial in the outer carton to protect it from light ²

**Contact your Teva Canada Hospital Key Account Manager
at 1-800-268-4129, for more information.**

For more information:

Please consult the Product Monograph at tevacanada.com/globalassets/canada-scs-files---global/product-monographs/truxima-product-monograph_en.pdf for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, administration (administered as an IV infusion through a dedicated line, not administered as an IV push or bolus) and conditions of clinical use, which have not been discussed in this piece. The Product Monograph is also available by calling Teva Canada Innovation at 1-833-662-5644.

References: 1. Data on File. First to market rituximab biosimilar. Teva Canada. May 31, 2019. 2. TRUXIMA® Product Monograph. Teva Canada Limited. August 22, 2024. 3. Jennette JC, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum.* 2013;65(1):1-11. 4. Biotec Services International Ltd. TRUXIMA® Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/truxima-epar-product-information_en.pdf. Accessed March 12, 2025.

Pr Truxima®
Rituximab for Injection
10 mg/mL Intravenous Infusion

Rituxan® is a registered trademark of IDEC Pharmaceuticals Corporation, used under license.

PrTRUXIMA® is a registered trademark of Celltrion Inc.

© 2025 Teva Canada Innovation G.P. - S.E.N.C. Montreal, Quebec, H2Z 1S8

04/2026
TRUX-CA-00152E

